<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32684139</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Enzyme-linked immunosorbent assays using virus-like particles containing mutations of conserved residues on envelope protein can distinguish three flavivirus infections.</ArticleTitle><Pagination><StartPage>1722</StartPage><EndPage>1732</EndPage><MedlinePgn>1722-1732</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2020.1797540</ELocationID><Abstract><AbstractText>The recent outbreaks of Zika virus (ZIKV) in flavivirus-endemic regions highlight the need for sensitive and specific serological tests. Previously we and others reported key fusion loop (FL) residues and/or BC loop (BCL) residues on dengue virus (DENV) envelope protein recognized by flavivirus cross-reactive human monoclonal antibodies and polyclonal sera. To improve ZIKV serodiagnosis, we employed wild type (WT) and FL or FL/BCL mutant virus-like particles (VLP) of ZIKV, DENV1 and West Nile virus (WNV) in enzyme linked immunosorbent assays (ELISA), and tested convalescent-phase serum or plasma samples from reverse-transcription PCR-confirmed cases with different ZIKV, DENV and WNV infections. For IgG ELISA, ZIKV WT-VLP had a sensitivity of 100% and specificity of 52.9%, which was improved to 83.3% by FL/BCL mutant VLP and 92.2% by the ratio of relative optical density of mutant to WT VLP. Similarly, DENV1 and WNV WT-VLP had a sensitivity/specificity of 100%/70.0% and 100%/56.3%, respectively; the specificity was improved to 93.3% and 83.0% by FL mutant VLP. For IgM ELISA, ZIKV, DENV1 and WNV WT-VLP had a specificity of 96.4%, 92.3% and 91.4%, respectively, for primary infection; the specificity was improved to 93.7-99.3% by FL or FL/BCL mutant VLP. An algorithm based on a combination of mutant and WT-VLP IgG ELISA is proposed to discriminate primary ZIKV, DENV and WNV infections as well as secondary DENV and ZIKV infection with previous DENV infections; this could be a powerful tool to better understand the seroprevalence and pathogenesis of ZIKV in regions where multiple flaviviruses co-circulate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Wen-Yang</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driesse</LastName><ForeName>Kaitlin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jih-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Szu-Chia</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sznajder Granat</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Center for Disease Control and Prevention, US Department of Health and Human Service, Fort Collins, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei-Kung</ForeName><Initials>WK</Initials><Identifier Source="ORCID">0000-0002-6670-4663</Identifier><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 GM114737</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI110769</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI149502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI135292</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014901" MajorTopicYN="N">West Nile Fever</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014902" MajorTopicYN="N">West Nile virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Zika virus</Keyword><Keyword MajorTopicYN="N">flavivirus</Keyword><Keyword MajorTopicYN="N">fusion loop</Keyword><Keyword MajorTopicYN="N">serodiagnosis</Keyword><Keyword MajorTopicYN="N">virus-like particles</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32684139</ArticleId><ArticleId IdType="pmc">PMC7473235</ArticleId><ArticleId IdType="doi">10.1080/22221751.2020.1797540</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lessler J, Chaisson LH, Kucirka LM, et al. . Assessing the global threat from Zika virus. Science. 2016;353:aaf8160. doi: 10.1126/science.aaf8160</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8160</ArticleId><ArticleId IdType="pmc">PMC5467639</ArticleId><ArticleId IdType="pubmed">27417495</ArticleId></ArticleIdList></Reference><Reference><Citation>Musso D, Ko AI, Baud D.. Zika virus infection &#x2013; after the pandemic. N Engl J Med. 2019;381:1444&#x2013;1457. doi: 10.1056/NEJMra1808246</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1808246</ArticleId><ArticleId IdType="pubmed">31597021</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance for US Laboratories testing for Zika virus infection. From CDC&#x2019;s website: http://www.cdc.gov/zika/laboratories/lab-guidance.html.</Citation></Reference><Reference><Citation>Pierson TC, Diamond MS.. Flaviviruses In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott William &amp; Wilkins; 2013. p. 747&#x2013;794.</Citation></Reference><Reference><Citation>Martin DA, Muth DA, Brown T, et al. . Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol. 2000;38:1823&#x2013;1826. doi: 10.1128/JCM.38.5.1823-1826.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.38.5.1823-1826.2000</ArticleId><ArticleId IdType="pmc">PMC86599</ArticleId><ArticleId IdType="pubmed">10790107</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AJ, Martin DA, Karabatsos N, et al. . Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38:1827&#x2013;1831. doi: 10.1128/JCM.38.5.1827-1831.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.38.5.1827-1831.2000</ArticleId><ArticleId IdType="pmc">PMC86600</ArticleId><ArticleId IdType="pubmed">10790108</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, et al. . Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313&#x2013;319. doi: 10.1038/nature02165</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02165</ArticleId><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, et al. . Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631&#x2013;6643. doi: 10.1128/JVI.00316-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, et al. . Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4:e4991. doi: 10.1371/journal.pone.0004991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Williams KL, Wu YC, et al. . Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis. 2013;7:e2451. doi: 10.1371/journal.pntd.0002451</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002451</ArticleId><ArticleId IdType="pmc">PMC3777924</ArticleId><ArticleId IdType="pubmed">24069496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Lai CY, Wu YC, et al. . High avidity and potent neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol. 2013;87:12562&#x2013;12575. doi: 10.1128/JVI.00871-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00871-13</ArticleId><ArticleId IdType="pmc">PMC3838129</ArticleId><ArticleId IdType="pubmed">24027331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanciotti RS, Kosoy OL, Laven JJ, et al. . Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232&#x2013;1239. doi: 10.3201/eid1408.080287</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1408.080287</ArticleId><ArticleId IdType="pmc">PMC2600394</ArticleId><ArticleId IdType="pubmed">18680646</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BW, Kosoy O, Martin DA, et al. . West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. Vector Borne Zoonotic Dis. 2005;5:137&#x2013;145. doi: 10.1089/vbz.2005.5.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vbz.2005.5.137</ArticleId><ArticleId IdType="pubmed">16011430</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meer MPA, M&#xf6;gling R, Klaasse J, et al. . Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence. J Clin Virol. 2017;92:25&#x2013;31. doi: 10.1016/j.jcv.2017.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.05.001</ArticleId><ArticleId IdType="pubmed">28505571</ArticleId></ArticleIdList></Reference><Reference><Citation>Felix AC, Souza NCS, Figueiredo WM, et al. . Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection. J Med Virol. 2017;89:1477&#x2013;1479. doi: 10.1002/jmv.24789</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24789</ArticleId><ArticleId IdType="pubmed">28229481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlenghi I, Clarke M, Ruttan T, et al. . Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell. 2001;7:593&#x2013;602. doi: 10.1016/S1097-2765(01)00206-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(01)00206-4</ArticleId><ArticleId IdType="pubmed">11463384</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalich J, Allison SL, Stiasny K, et al. . Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol. 1996;70:4549&#x2013;4557. doi: 10.1128/JVI.70.7.4549-4557.1996</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.70.7.4549-4557.1996</ArticleId><ArticleId IdType="pmc">PMC190391</ArticleId><ArticleId IdType="pubmed">8676481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz IC, Kartenbeck J, Mezzacasa A, et al. . Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol. 2003;77:4370&#x2013;4382. doi: 10.1128/JVI.77.7.4370-4382.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.7.4370-4382.2003</ArticleId><ArticleId IdType="pmc">PMC150630</ArticleId><ArticleId IdType="pubmed">12634393</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis BS, Chang GJ, Cropp B, et al. . West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol. 2001;75:4040&#x2013;4047. doi: 10.1128/JVI.75.9.4040-4047.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.9.4040-4047.2001</ArticleId><ArticleId IdType="pmc">PMC114149</ArticleId><ArticleId IdType="pubmed">11287553</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou SS, Crill WD, Chen LK, et al. . Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol. 2008;15:825&#x2013;835. doi: 10.1128/CVI.00004-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00004-08</ArticleId><ArticleId IdType="pmc">PMC2394851</ArticleId><ArticleId IdType="pubmed">18337381</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson JA, Crill WD, Chang GJ.. Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol. 2007;45:3167&#x2013;3174. doi: 10.1128/JCM.01143-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01143-07</ArticleId><ArticleId IdType="pmc">PMC2045342</ArticleId><ArticleId IdType="pubmed">17715375</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, et al. . Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA. 2012;109:7439&#x2013;7444. doi: 10.1073/pnas.1200566109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, et al. . A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014;6:358&#x2013;371. doi: 10.1002/emmm.201303404</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201303404</ArticleId><ArticleId IdType="pmc">PMC3958310</ArticleId><ArticleId IdType="pubmed">24421336</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Wongwiwat W, Supasa S, et al. . A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16:170&#x2013;177. doi: 10.1038/ni.3058</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3058</ArticleId><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh EP, Kukkaro PP, Teo EW, et al. . The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012;4:139ra83. doi: 10.1126/scitranslmed.3003888</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003888</ArticleId><ArticleId IdType="pubmed">22723463</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhagen K, Probst C, Radzimski C, et al. . Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21:30426. doi: 10.2807/1560-7917.ES.2016.21.50.30426</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.50.30426</ArticleId><ArticleId IdType="pmc">PMC5291135</ArticleId><ArticleId IdType="pubmed">28006649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig Y, Zelena H, Venturi G, et al. . Sensitivity and kinetics of an NS1-based Zika virus enzyme-linked immunosorbent assay in Zika virus-infected travelers from Israel, the Czech Republic, Italy, Belgium, Germany, and Chile. J Clin Microbiol. 2017;55:1894&#x2013;1901. doi: 10.1128/JCM.00346-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00346-17</ArticleId><ArticleId IdType="pmc">PMC5442546</ArticleId><ArticleId IdType="pubmed">28381608</ArticleId></ArticleIdList></Reference><Reference><Citation>Safronetz D, Sloan A, Stein DR, et al. . Evaluation of 5 commercially available Zika virus immunoassays. Emerg Infect Dis. 2017;23:1577&#x2013;1580. doi: 10.3201/eid2309.162043</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2309.162043</ArticleId><ArticleId IdType="pmc">PMC5572859</ArticleId><ArticleId IdType="pubmed">28665268</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmaseda A, Zambrana JV, Collado D, et al. . Comparison of four serological methods and two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection. J Clin Microbiol. 2018;56:e01785&#x2013;17. doi: 10.1128/JCM.01785-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01785-17</ArticleId><ArticleId IdType="pmc">PMC5824050</ArticleId><ArticleId IdType="pubmed">29305550</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Youn HH, Brites C, et al. . Distinguishing secondary dengue virus infection from Zika virus infection with previous dengue by combination of three simple serological tests. Clin Infect Dis. 2017;65:1829&#x2013;1836. doi: 10.1093/cid/cix672</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix672</ArticleId><ArticleId IdType="pmc">PMC5850648</ArticleId><ArticleId IdType="pubmed">29020159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson J, Tsai WY, Tsai JJ, et al. . Combination of non-structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish various dengue virus and Zika virus infections. J Clin Microbiol. 2019;57:e01464&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6355536</ArticleId><ArticleId IdType="pubmed">30429254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson J, Tsai WY, Tsai JJ, et al. . A high-throughput and multiplex microsphere immunoassay based on non-structural protein 1 can discriminate three flavivirus infections. PLoS Negl Trop Dis. 2019;13:e0007649. doi: 10.1371/journal.pntd.0007649</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007649</ArticleId><ArticleId IdType="pmc">PMC6707547</ArticleId><ArticleId IdType="pubmed">31442225</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Collins M, Graham S, et al. . Development of envelope protein antigens to serologically differentiate Zika virus infection from dengue virus infection. J Clin Microbiol. 2018;56:e01504&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824056</ArticleId><ArticleId IdType="pubmed">29263206</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao DY, Whitney MT, Davis BS, et al. . Comprehensive evaluation of differential serodiagnosis between Zika and dengue viral infections. J Clin Microbiol. 2019;57:e01506&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425182</ArticleId><ArticleId IdType="pubmed">30541932</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabierski S, Barzon L, Papa A, et al. . Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis. 2014;14:246. doi: 10.1186/1471-2334-14-246</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-246</ArticleId><ArticleId IdType="pmc">PMC4028281</ArticleId><ArticleId IdType="pubmed">24884467</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockstroh A, Barzon L, Pacenti M, et al. . Recombinant envelope-proteins with mutations in the conserved fusion loop allow specific serological diagnosis of dengue-infections. PLoS Negl Trop Dis. 2015;9:e0004218. doi: 10.1371/journal.pntd.0004218</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004218</ArticleId><ArticleId IdType="pmc">PMC4643925</ArticleId><ArticleId IdType="pubmed">26565964</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockstroh A, Moges B, Barzon L, et al. . Specific detection of dengue and Zika virus antibodies using envelope proteins with mutations in the conserved fusion loop. Emerg Microbes Infect. 2017;6:e99. doi: 10.1038/emi.2017.87</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2017.87</ArticleId><ArticleId IdType="pmc">PMC5717088</ArticleId><ArticleId IdType="pubmed">29116222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Supasa P, Wongwiwat W, et al. . Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17:1102&#x2013;1108. doi: 10.1038/ni.3515</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3515</ArticleId><ArticleId IdType="pmc">PMC4994874</ArticleId><ArticleId IdType="pubmed">27339099</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyamvada L, Quicke KM, Hudson WH, et al. . Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113:7852&#x2013;7857. doi: 10.1073/pnas.1607931113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1607931113</ArticleId><ArticleId IdType="pmc">PMC4948328</ArticleId><ArticleId IdType="pubmed">27354515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardina SV, Bunduc P, Tripathi S, et al. . Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356:175&#x2013;180. doi: 10.1126/science.aal4365</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal4365</ArticleId><ArticleId IdType="pmc">PMC5714274</ArticleId><ArticleId IdType="pubmed">28360135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore APS, Saron WAA, Lim T, et al. . Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. Sci Adv. 2019;5:eaav3208. doi: 10.1126/sciadv.aav3208</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aav3208</ArticleId><ArticleId IdType="pmc">PMC6392794</ArticleId><ArticleId IdType="pubmed">30820456</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken MK, Gromowski GD, Friberg HL, et al. . Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. PLoS Pathog. 2017;13:e1006487. doi: 10.1371/journal.ppat.1006487</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006487</ArticleId><ArticleId IdType="pmc">PMC5542404</ArticleId><ArticleId IdType="pubmed">28771605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantoja P, P&#xe9;rez-Guzm&#xe1;n EX, Rodr&#xed;guez IV, et al. . Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017;8:15674. doi: 10.1038/ncomms15674</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15674</ArticleId><ArticleId IdType="pmc">PMC5490051</ArticleId><ArticleId IdType="pubmed">28643775</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg Infect Dis. 2017;23:569&#x2013;573. doi: 10.3201/eid2304.161879</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2304.161879</ArticleId><ArticleId IdType="pmc">PMC5367429</ArticleId><ArticleId IdType="pubmed">28322690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A, Gresh L, Ojeda S, et al. . Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS Med. 2019;16:e1002726. doi: 10.1371/journal.pmed.1002726</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002726</ArticleId><ArticleId IdType="pmc">PMC6342296</ArticleId><ArticleId IdType="pubmed">30668565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Barraquer I, Costa F, Nascimento EJM, et al. . Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science. 2019;363:607&#x2013;610. doi: 10.1126/science.aav6618</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav6618</ArticleId><ArticleId IdType="pubmed">30733412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan G, Gordon A, Avil&#xe9;s W, et al. . The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol. 2009;170:120&#x2013;129. doi: 10.1093/aje/kwp092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp092</ArticleId><ArticleId IdType="pmc">PMC2700880</ArticleId><ArticleId IdType="pubmed">19435864</ArticleId></ArticleIdList></Reference><Reference><Citation>Narvaez F, Gutierrez G, Perez MA, et al. . Evaluation of the traditional and revised WHO classifications of dengue disease severity. PLoS Negl Trop Dis. 2011;5:e1397. doi: 10.1371/journal.pntd.0001397</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001397</ArticleId><ArticleId IdType="pmc">PMC3210746</ArticleId><ArticleId IdType="pubmed">22087348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stramer SL, Fang CT, Foster GA, et al. . West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451&#x2013;459. doi: 10.1056/NEJMoa044333</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa044333</ArticleId><ArticleId IdType="pubmed">16079368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WK, Chen HL, Yang CF, et al. . Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis. 2006;43:1023&#x2013;1030. doi: 10.1086/507635</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/507635</ArticleId><ArticleId IdType="pubmed">16983615</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Chen HL, Tsai JJ, et al. . Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine. J Virol. 2018;92:e00556&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6232466</ArticleId><ArticleId IdType="pubmed">30185598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JJ, Liu CK, Tsai WY, et al. . Seroprevalence of dengue in two districts of Kaohsiung city after the largest dengue outbreak in Taiwan since world war II. PLoS Negl Trop Dis. 2018;12:e0006879. doi: 10.1371/journal.pntd.0006879</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006879</ArticleId><ArticleId IdType="pmc">PMC6218099</ArticleId><ArticleId IdType="pubmed">30356316</ArticleId></ArticleIdList></Reference><Reference><Citation>Klock HE, Lesley SA.. The polymerase incomplete primer extension (PIPE) method applied to high-throughput cloning and site-directed mutagenesis. Methods Mol Biol. 2009;498:91&#x2013;103. doi: 10.1007/978-1-59745-196-3_6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-196-3_6</ArticleId><ArticleId IdType="pubmed">18988020</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey A, Di Canzio J, Zurakowski D.. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221:35&#x2013;41. doi: 10.1016/S0022-1759(98)00170-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(98)00170-7</ArticleId><ArticleId IdType="pubmed">9894896</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, DeMaso CR, Pelc RS, et al. . Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 2016;16:1485&#x2013;1491. doi: 10.1016/j.celrep.2016.07.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.07.049</ArticleId><ArticleId IdType="pmc">PMC5004740</ArticleId><ArticleId IdType="pubmed">27481466</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya M, Collins M, Dejnirattisai W, et al. . Longitudinal analysis of antibody cross-neutralization following Zika virus and dengue virus infection in Asia and the Americas. J Infect Dis. 2018;218:536&#x2013;545. doi: 10.1093/infdis/jiy164</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy164</ArticleId><ArticleId IdType="pmc">PMC6047418</ArticleId><ArticleId IdType="pubmed">29618091</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Jordan JL. Diagnosis of Zika virus infections: challenges and opportunities. J Infect Dis. 2017;216(Suppl. 10):S951&#x2013;S956. doi: 10.1093/infdis/jix502</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix502</ArticleId><ArticleId IdType="pmc">PMC5853979</ArticleId><ArticleId IdType="pubmed">29267922</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G, Stone M, Busch MP.. Arbovirus diagnostics: from bad to worse due to expanding dengue virus vaccination and Zika virus epidemics. Clin Infect Dis. 2018;66:1181&#x2013;1183. doi: 10.1093/cid/cix972</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cix972</ArticleId><ArticleId IdType="pmc">PMC6248677</ArticleId><ArticleId IdType="pubmed">29301009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>